ArticleBMC rheumatology2025
Gastrointestinal involvement in granulomatosis with polyangiitis: frequency, clinical impact, and prognostic implications in a retrospective cohort study.
Article in BMC rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ANCA-Negative Granulomatous Polyangiitis Presenting With Isolated Oral and Esophageal Involvement.ACG case reports journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGranulomatosis with polyangiitis (GPA) is a rare form of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis that can involve multiple organ systems, including the gastrointestinal (GI) tract. Although GI manifestations are relatively uncommon, they may be associated with serious complications and adverse outcomes. This study aimed to assess the frequency and types of GI involvement in patients with GPA and to examine their relationship with disease severity, prognosis, and treatment response.
methodsIn this retrospective cohort study, clinical records of 220 patients with a confirmed diagnosis of GPA who were referred to Amir Alam Hospital between 2013 and 2021 were reviewed. Data on demographic characteristics, GI symptoms, Birmingham Vasculitis Activity Score (BVAS), therapeutic response, relapse rates, and mortality were collected and analyzed.
resultsGI involvement was observed in 18 patients (8.2%). The most common manifestations included hepatitis, mesenteric ischemia, diarrhea, pancreatitis, and elevated liver enzymes. Patients with GI involvement had significantly higher BVAS scores (mean 21 vs. 15.8, p = 0.004), a markedly increased mortality risk (hazard ratio = 3.24, p < 0.001), and a shorter time to first relapse (mean 5.2 vs. 10.3 months, p = 0.041) compared to those without GI symptoms.
conclusionGastrointestinal involvement in GPA is associated with more severe disease activity, diminished treatment response, and increased mortality. Early detection and appropriate management of GI manifestations may improve clinical outcomes. Further prospective studies are warranted to elucidate the underlying mechanisms and optimize treatment strategies for this high-risk subgroup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.